ABSTRACT
Since its inception in the 1980s, high-throughput screening (HTS) has become a standard aspect of the drug discovery process in pharmaceutical and biotechnology companies and has also recently been explored in academia (Tolliday et al., 2006). Current drug discovery relies on screening of chemical libraries against various molecular targets to nd lead compounds that serve as starting points for the drug development process. Technological development in HTS has been closely linked with advances in screen automation in the past two decades to increase throughput and reduce screen costs.
